Doesn't matter - short term capital gains taxed the same as codi. If they allocate me codi, it just reduces my gain. In fact, may be better since I may not have to pay the Medicare tax on codi
Eh. I lost a few mil the 2nd interim and will lose a few mil this time too. You pays your money and you takes your chances. I was way up on oil's recovery so the tax man participated with me to the tune of 40%
$6 a share cash, Ebola and indoximid. Hmmmm. $9 seems cheap when you look at the parts. But so far I've been on the wrong side of the fence
Of course - that's why they are keeping their shares. You asked why no insider transactions and that's the answer - they're buying their 'tax shares' in essence
"1,922,518 shares of Common Stock (includes 1,616,511 shares of Common Stock issuable upon exercise of options exercisable within 60 days of December 31, 2015). "
Those options had to have already been exercised. Thus the tax. No corresponding stock sale to pay the tax - that's what I'm talking about.
How many shares were bonused to the top dogs? They gotta pay taxes on those - how many did they sell for that? Speaks volumes the lack of a tax sale
....that this is going to be successful. They have some data information from the 2nd interim and know why it didn't stop at that time. These are very smart people, I'm certain they can do the math and see what an extra year+ with just 110 events would do to the results.
From Cantor July NLNK report:
"The IMPRESS trial is a Phase III trial of algenpantucel-L in patients with pancreatic cancer who have
undergone surgical resection. While there was disappointment surrounding the IMPRESS trial not
stopping at the 2nd interim analysis, at the July Analyst Day, NewLink shared an estimated median
overall survival of 28.5 months from the time to randomization for both cohorts blended
together. This compares to historical overall survival rates of 19.2 months for resected pancreatic
cancer patients and management estimates that overall survival in the control arm could be in the low
twenties, which incorporates advances in standard of care.
Additional incremental commentary suggests that the distribution of events does not appear to be a normal distribution, and that could be a factor in the lack of stopping at the second interim. With the trial employing a log rank analysis that compares the curves that are expected to have a normal distribution, interim stopping did not occur.However at final analysis, the company could have greater freedom to analyze results utilizing
alternative methodologies that take into account the lack of normal distribution. At present,
achievement of the primary endpoint is based on a log rank analysis powered at 80% to detect a 20%
difference in overall survival."
Even this board is sedate compared to the 2nd interim. None of the shorts are here blowing smoke - and few longs as well (in comparison)